FDA Approves Six on! PLUS Nicotine Pouch Products for Adult Sales in the US

The US Food and Drug Administration (FDA) has granted approval for adults to purchase six nicotine pouch products under the on! PLUS brand. This decision facilitates the legal sale of these items across the United States.

On Friday, the FDA announced this approval as part of a new pilot initiative aimed at expediting the review process for select tobacco and nicotine products. This marks the inaugural approval through this fast-tracked system, which began in September.

These six products are manufactured by Helix Innovations LLC, a collaboration that involves Altria. The company sought permission for these goods in June 2024. After evaluating the scientific data, the FDA concluded that they met the necessary standards for market entry.

The approved on! PLUS nicotine pouches are available in mint, tobacco, and wintergreen flavors, offered in two nicotine levels: 6 milligrams and 9 milligrams. They can now be legally marketed to adults across the US.

The FDA's decision considers evidence indicating that these nicotine pouches contain significantly lower levels of harmful chemicals in comparison to conventional smokeless tobacco products. Consequently, they are viewed as carrying a reduced risk of cancer and various serious health issues.

It should be noted that this authorization is exclusive to the six specified products. Other nicotine pouch items produced by the same company would need individual approval before they can be sold.

Nicotine pouches are small sachets that are positioned under the upper lip, eliminating the need for smoke, burning, or tobacco leaves. Due to the absence of inhalation, they are often regarded as lower-risk alternatives to both cigarettes and other smokeless tobacco.

In the US, nicotine pouches have emerged as the fastest-growing segment in the nicotine product market. Many adult smokers are opting for them as cigarette use decreases.

Earlier this year, the FDA authorized 20 Zyn nicotine pouch products from Philip Morris International, marking the first approvals in this category, although their review spanned over five years.

Major tobacco firms are heavily investing in smoke-free and reduced-risk products as they adapt to evolving consumer preferences and stricter health regulations. These companies assert that such products may assist adult smokers in moving away from cigarettes.

Following this announcement, Altria revealed it would resume taking new orders for on! PLUS nicotine pouches in states including Florida, North Carolina, and Texas, along with availability through online channels.

Health officials continue to stress that nicotine carries risks. The US Centers for Disease Control and Prevention warns that nicotine can adversely affect brain development in teenagers, influencing learning, attention, mood, and self-regulation.

For this reason, the FDA emphasized that these approved products are intended solely for adult users and should not be accessible to children or adolescents. The agency will maintain oversight on how these products are marketed and sold.

This approval exemplifies regulators' attempts to strike a balance between assisting adult smokers in finding lower-risk options while safeguarding youths from nicotine addiction. As new products continuously enter the market, this equilibrium is expected to remain a prominent public health challenge.